ChemoCentryx Inc - ESG Rating & Company Profile powered by AI
Complete ESG analysis of ChemoCentryx Inc are accessed by registering for free. Alternative companies in the scoring peer group for ChemoCentryx Inc are displayed below. This SDG assessment for ChemoCentryx Inc represents its transparency towards the United Nations SDGs.
ChemoCentryx Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.0, social score of 3.2 and governance score of 4.8.
3.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1234 | Quanterix Corp | 3.4 | Medium |
| 1234 | X4 Pharmaceuticals Inc | 3.4 | Medium |
| 1253 | ChemoCentryx Inc | 3.3 | Medium |
| 1253 | Calithera Biosciences Inc | 3.3 | Medium |
| 1253 | Cara Therapeutics Inc | 3.3 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ChemoCentryx Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ChemoCentryx Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes ChemoCentryx Inc report the average age of the workforce?
Sign up for free to unlockDoes ChemoCentryx Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ChemoCentryx Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes ChemoCentryx Inc disclose cybersecurity risks?
Sign up for free to unlockDoes ChemoCentryx Inc offer flexible work?
Sign up for free to unlockDoes ChemoCentryx Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ChemoCentryx Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ChemoCentryx Inc conduct supply chain audits?
Sign up for free to unlockDoes ChemoCentryx Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ChemoCentryx Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes ChemoCentryx Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes ChemoCentryx Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ChemoCentryx Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ChemoCentryx Inc disclose water use targets?
Sign up for free to unlockDoes ChemoCentryx Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid ChemoCentryx Inc have a product recall in the last two years?
Sign up for free to unlockDoes ChemoCentryx Inc disclose incidents of discrimination?
Sign up for free to unlockDoes ChemoCentryx Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ChemoCentryx Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ChemoCentryx Inc disclose parental leave metrics?
Sign up for free to unlockDoes ChemoCentryx Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ChemoCentryx Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ChemoCentryx Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes ChemoCentryx Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ChemoCentryx Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ChemoCentryx Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ChemoCentryx Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes ChemoCentryx Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ChemoCentryx Inc disclose its waste policy?
Sign up for free to unlockDoes ChemoCentryx Inc report according to TCFD requirements?
Sign up for free to unlockDoes ChemoCentryx Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ChemoCentryx Inc disclose energy use targets?
Sign up for free to unlockDoes ChemoCentryx Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ChemoCentryx Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ChemoCentryx Inc
These potential risks are based on the size, segment and geographies of the company.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.